Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia

Trial Profile

XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Adverse reactions
  • Acronyms XALIA LEA
  • Sponsors Bayer
  • Most Recent Events

    • 12 Dec 2017 Results of pooled analysis of the XALIA and XALIA-LEA studies assessing tolerability and efficacy of rivaroxaban in patients with acute venous thromboembolism, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 16 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 05 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top